• Explore /
  • Poster
  • / Clinical outcomes in phase 1 clinical trials (Ph1-CT) when treating patients (pts) with novel immunotherapy (IT) agents at early lines for advanced disease.

Clinical outcomes in phase 1 clinical trials (Ph1-CT) when treating patients (pts) with novel immunotherapy (IT) agents at early lines for advanced disease.

Abstract Poster

Authors

null

Juan José Soto

Medical Oncology Department-Phase 1 Functional Unit | Catalan Institute of Oncology (ICO), Hospitalet De Llobregat, Barcelona, Spain

Juan José Soto , Sandra Llop-Serna , Agostina Stradella , Rafael Villanueva , Mariona Calvo , Maria Jove , Jose Carlos Ruffinelli , Carmen Cuadra Amor , Ramon Salazar , Miguel J. Gil Gil , Marta Gil-Martin , Marc Oliva , Juan Martin Liberal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 2586)

DOI

10.1200/JCO.2023.41.16_suppl.2586

Abstract #

2586

Poster Bd #

428

Abstract Disclosures

Similar Posters

First Author: Juan José Soto

First Author: Takayuki Nakayama

First Author: Julie M. Shabto

First Author: Hazel Lote